Clinical Trials Directory

Trials / Completed

CompletedNCT00621725

Phase 1 PK Study of Cediranib in Single and Multiple Doses in Hepatically Impaired Patients With Solid Tumours

A Phase I, Open Label Study of the Pharmacokinetics and Safety of Cediranib (RECENTINTM, AZD2171) Following Single and Multiple Oral Doses in Patients With Advanced Solid Tumours With Various Degrees of Hepatic Dysfunction

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
36 (actual)
Sponsor
AstraZeneca · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

To determine how patients with advanced cancer and various degrees of hepatic impairment will metabolise Cediranib.

Conditions

Interventions

TypeNameDescription
DRUGAZD2171Oral dose

Timeline

Start date
2008-01-01
Primary completion
2010-07-01
Completion
2014-01-01
First posted
2008-02-22
Last updated
2014-07-15

Locations

3 sites across 2 countries: Denmark, Netherlands

Source: ClinicalTrials.gov record NCT00621725. Inclusion in this directory is not an endorsement.